Compare PII & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | ADMA |
|---|---|---|
| Founded | 1954 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 1987 | N/A |
| Metric | PII | ADMA |
|---|---|---|
| Price | $68.06 | $19.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $52.80 | $28.50 |
| AVG Volume (30 Days) | 788.8K | ★ 2.9M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | N/A | ★ 0.86 |
| Revenue | ★ $7,076,200,000.00 | $488,559,000.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | $0.13 | $24.33 |
| P/E Ratio | ★ N/A | $23.11 |
| Revenue Growth | N/A | ★ 27.63 |
| 52 Week Low | $30.92 | $13.50 |
| 52 Week High | $75.25 | $25.67 |
| Indicator | PII | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 66.02 |
| Support Level | $66.18 | $19.13 |
| Resistance Level | $71.25 | $20.22 |
| Average True Range (ATR) | 2.29 | 0.73 |
| MACD | 0.35 | 0.05 |
| Stochastic Oscillator | 62.55 | 79.44 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.